Antiplatelet therapy: present status and its future directions


  • Kaza Ahluwalia Department of Pharmacology,Government Medical College and Hospital,Sector- 32,Chandigarh, India
  • Sangeeta Bhanwra Department of Pharmacology,Government Medical College and Hospital,Sector- 32,Chandigarh, India


Anti-platelets, Thrombin receptor antagonists, Collagen receptor antagonists, P2Y12 antagonists


Anti-platelets drugs play an important role in the prevention or treatment of cardiovascular diseases e.g. coronary artery disease, stroke, etc., which cause high mortality and morbidity in the present day world. These drugs either inhibit the platelet activation, aggregation or other signaling pathways, thereby inhibiting the clot formation. The anti-platelet drugs currently used are aspirin, ADP receptor inhibitors (ticlopidine and clopidogrel)and glycoprotein (GP)IIb/IIIa inhibitors (abciximab, tirofiban and eptifibatide). Aspirin was and still continues to be the main anti-platelet therapy. A combination regimen of aspirin and clopidogrel is commonly used for the prevention of platelet activation, thrombosis and stroke. However, many of the current anti-platelet drugs face limitations due to narrow therapeutic window and limited efficacy. The four possible targets for novel anti-platelet action are: Inhibition of agonist generation, receptor inhibition, G protein inhibition and inhibition of enzymatic cascades. Newer P2Y12 antagonists e.g. prasugrel, ticagrelor, cangrelor, etc., have better efficacy and low bleeding risk. The thrombin receptor (PAR1 and 4) inhibitors are said to decrease the hemorrhagic complications. Drugs which inhibit TXA2 Synthase or TXA2 receptor are also promising in their anti-platelet action. Another novel group is of collagen receptor antagonists such as GPVI antagonists, GPIb receptor antagonists, etc. The other targets being explored are von Willebrand Factor antagonists, platelet Gq antagonists, etc. However, there still lies a bundle of unresolved issues regarding the efficacy and safety, optimal dosage, administration requirements, combination therapy, clinical evaluation, cost-effectiveness, and the resistance phenomena of these drugs.


Yeung J, Holinstat M. Newer agents in antiplatelet therapy: a review. J Blood Med. 2012;3:33-42. [DOI via Crossref]

Xiang YZ, Xia Y, Gao XM, Shang HC, Kang LY, Jhang BL. Platelet activation and antiplatelet targets and agents: current and novel strategies. Drugs. 2008;68(12):1647-64. [DOI via Crossref]

Penela D, Diaz-Ricart M, Heras M. New antiplatelet drugs in perspective. Eur Cardiol. 2011;7(3):216-9.

Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res. 2004;114(5-6):447-53. [DOI via Crossref]

Blood drugs. In: Harvey RA, Champe PC, editors. Lippincott's Illustrated Reviews Pharamcology. 4th Edition. New Delhi: Wolters Kluwer; 2009: 229-48.

Thijs T, Nuyttens BP, Deckmyn H, Broos K. Platelet physiology and antiplatelet agents. Clin Chem Lab Med. 2010;48 Suppl 1:S3-13. [DOI via Crossref]

Majerus PW, Tollefsen DM. Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th Edition. United States of Americas: McGraw-Hill; 2006: 1467-88.

Berger JS, Brown DL, Becker RC. Low dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med. 2008;121(1):43-9. [DOI via Crossref]

Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007;297(18):2018-24. [DOI via Crossref]

Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low dose aspirin for secondary cardiovascular prevention-cardiovascular risk after its perioperative withdrawal versus bleeding risks with its continuation: review and metanalysis. J Intern Med. 2005;257(5):399-414. [DOI via Crossref]

Schror K. The basic pharmacology of ticlopidine and clopidogrel. Platelets. 1993;4(5):252-61. [DOI via Crossref]

Bellavance A. Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The ticlopidine aspirin stroke study. Stroke. 1993;24(10):1452-7. [DOI via Crossref]

Husted S. New developments in oral antiplatelet therapy. Eur Heart J. 2007;9 Suppl D:D20-7.

Lippi G, Montagnana M, Danese E, Favaloro EJ, Franchini M. Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess anti-platelet efficacy. Biomark Med. 2011;5:63-70. [DOI via Crossref]

Ji X, Hou M. Novel agents for anti-platelet therapy. J Hematol Oncol. 2011;4:44. [DOI via Crossref]

Tantry US, Bliden KP, Wei C. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Cir Cardiovasc Genet. 2010;3(6):556-66. [DOI via Crossref]

Mahaffey KW, Wojdyla DM, Carroll K, Carroll K, Becker RC, Storey RF, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124(5):544-54. [DOI via Crossref]

Ueno M, Ferreiro JL, Angiolillo DJ. Update on the clinical development of cangrelor. Expert Rev Cardiovasc Ther. 2010;8:1069-77. [DOI via Crossref]

Berger JS, Roe MT, Gibson CM, Kilaru R, Green CL, Melton L, et al. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid Reversal of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J. 2009;158(6):998-1004. [DOI via Crossref]

Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407(6801):258-64. [DOI via Crossref]

Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, et al. Vorapaxar in the secondary prevention of the atherothrombotic events. N Engl J Med. 2012;366:1404-13. [DOI via Crossref]

Morrow DA, Alberts MJ, Mohr JP, Ameriso SF, Bonaca MP, Goto S, et al. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013;44(3):691-8. [DOI via Crossref]

Wu CC, Teng CM. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation. Eur J Pharmacol. 2006;546(1-3):142-7. [DOI via Crossref]

Ungerer M, Rosport K, Bultmann A. Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation. 2011;123(17):1891-9. [DOI via Crossref]

Zafar MU, Ibanez B, Choi BG, Vorchheimer DA, Pi-ero A, Jin X, et al. A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost. 2010;103(1):205-12. [DOI via Crossref]

Kageyama S, Yamamoto H, Nakazawa H, Matsushita J, Kouyama T, Gonsho A, et al. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler Thromb Vasc Biol. 2002;22(1):187-92. [DOI via Crossref]

Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation. 2007;116(23):2678-86. [DOI via Crossref]

Knobl P, Jilma B, Gilbert JC, Hutabarat RM, Wagner PG, Jilma-Stohlawetz P. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion. 2009;49(10):2181-5. [DOI via Crossref]

Siller-Matula JM, Merhi Y, Tanguay JF, Duerschmied D, Wagner DD, McGinness KE, et al. ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. Arterioscler Thromb Vasc Biol. 2012;32(4):902-9. [DOI via Crossref]

Vorchheimer DA, Fuster V. Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety. Circulation 1998;97:312-4. [DOI via Crossref]

Uemura T, Kawasaki T, Taniguchi M, et al. Biological properties of a specific G alpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress. Br J Pharmacol. 2006;148(1):61-9. [DOI via Crossref]

Rieken S, Sassmann A, Herroeder S, et al. G12/G13 family G proteins regulate marginal zone B cell maturation, migration, and polarization. J Immunol. 2006;177(5):2985-93.

Wettschureck N, Lee E, Libutti SK, et al. Parathyroid-specific double knockout of Gq and G11 alpha-subunits leads to a phenotype resembling germline knockout of the extracellular Ca2+-sensing receptor. Mol Endocrinol. 2007;21(1):274-80. [DOI via Crossref]

Lee JH, Cha JK, Lee SJ, Ha SW, Kwon SU. Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. Eur J Neurol. 2010;17:434-42. [DOI via Crossref]

Patscheke H, Hornberger W, Zehender H. Pathophysiological role of thromboxane A2 and pharmacological approaches to its inhibition. Z Kardiol. 1990;79 Suppl 3:151-4.

FitzGerald GA, Reilly IA, Pedersen AK. The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation. 1985;72(6):1194-201. [DOI via Crossref]

Neri Serneri GG, Coccheri S, Marubini E, Violi F. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J. 2004;25(20):1845-52. [DOI via Crossref]

Luderer JR, Nicholas GG, Neumyer MM, Riley DL, Vary JE, Garcia G, et al. Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon. Clin Pharmacol Ther. 1984;36(1):105-15. [DOI via Crossref]

Robert F. The potential benefits of low-molecular-weight heparins in cancer patients. J Hematol Oncol. 2010;3:3. [DOI via Crossref]

Budhu A, Ji J, Wang XW. The clinical potential of microRNAs. J Hematol Oncol. 2010;3:37. [DOI via Crossref]




How to Cite

Ahluwalia, K., & Bhanwra, S. (2017). Antiplatelet therapy: present status and its future directions. International Journal of Basic & Clinical Pharmacology, 3(2), 260–268. Retrieved from



Review Articles